The recommendation is specifically for use in patients who have achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation (HSCT).
AML is one of the most common acute leukaemias in adults, with around 3,100 new diagnoses of the disease in the UK per year – a 20% increase in incident rates. since the early 1990s. Incidence of the disease is strongly related to age, with 42% of all new cases in the UK each year being diagnosed in people aged 75 and over…
